<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               2 DOSAGE AND ADMINISTRATION<BR>               <BR>               <BR>                  <BR>                     <BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><BR>                           <col width="105%"/><BR>                           <col width="11%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td styleCode="Rrule Botrule Lrule Toprule "><BR>                                    <paragraph>When given with potent CYP3A inhibitors (with or without potent CYP3A inducers) including PIs (except tipranavir/ritonavir), delavirdine (2, 7.1)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule Toprule "><BR>                                    <paragraph>150 mg</paragraph><BR>                                    <paragraph>twice daily</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>With NRTIs, tipranavir/ritonavir, nevirapine, raltegravir, and other drugs that are not potent CYP3A inhibitors or CYP3A inducers (2, 7.1)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>300 mg</paragraph><BR>                                    <paragraph>twice daily</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Botrule Lrule "><BR>                                    <paragraph>With potent CYP3A inducers including efavirenz (without a potent CYP3A inhibitor) (2, 7.1)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>600 mg</paragraph><BR>                                    <paragraph>twice daily</paragraph><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>A more complete list of coadministered drugs is listed in Dosage and Administration (2).<BR>                        Dose adjustment may be necessary in patients with renal impairment. (2.2)<BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.1 Dose Recommendations for Patients With Normal Renal Function <BR>                     <BR>                        The recommended dose of SELZENTRY differs based on concomitant medications due to drug interactions (see Table 1). SELZENTRY can be taken with or without food. SELZENTRY must be given in combination with other antiretroviral medications.<BR>                        Table 1 gives the recommended dose adjustments [see Drug Interactions (7.1)].<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="_Refid_01905207-d216-4ac5-beaa-aa7e057ad"><BR>                           <caption>Table 1. Recommended Dosing Regimen</caption><BR>                           <col width="93%"/><BR>                           <col width="22%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td align="center" styleCode="Rrule Botrule Lrule Toprule "><BR>                                    <paragraph>Concomitant Medications</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule Toprule "><BR>                                    <paragraph>Dose of SELZENTRY</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Potent CYP3A inhibitors (with or without a potent CYP3A inducer) including:</paragraph><BR>                                    <list listType="unordered"><BR>                                       <item>protease inhibitors (except tipranavir/ritonavir)</item><BR>                                       <item>delavirdine</item><BR>                                       <item>ketoconazole, itraconazole, clarithromycin</item><BR>                                       <item>other potent CYP3A inhibitors (e.g., nefazodone, telithromycin)</item><BR>                                    </list><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>150&#160;mg twice daily</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Other concomitant medications, including tipranavir/ritonavir, nevirapine, raltegravir, all NRTIs, and enfuvirtide </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>300&#160;mg twice daily</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Botrule Lrule "><BR>                                    <paragraph>Potent CYP3A inducers (without a potent CYP3A inhibitor) including:</paragraph><BR>                                    <list listType="unordered"><BR>                                       <item>efavirenz</item><BR>                                       <item>rifampin</item><BR>                                       <item>etravirine</item><BR>                                       <item>carbamazepine, phenobarbital, and phenytoin</item><BR>                                    </list><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>600&#160;mg twice daily</paragraph><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                     <BR><BR><BR><BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     2.2 Dose Recommendations for Patients With Renal Impairment<BR>                     <BR>                        Table 2 provides dosing recommendations for patients based on renal function and concomitant medications.<BR>                        <BR><BR><table xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" ID="_Refid_eafac2fc-3a31-47af-83ae-df3505b77"><BR>                           <caption>Table 2. Recommended Dosing Regimens Based on Renal Function</caption><BR>                           <col width="32%"/><BR>                           <col width="15%"/><BR>                           <col width="17%"/><BR>                           <col width="18%"/><BR>                           <col width="14%"/><BR>                           <col width="19%"/><BR>                           <tbody><BR>                              <tr><BR>                                 <td align="center" rowspan="2" styleCode="Rrule Botrule Lrule Toprule "><BR>                                    <paragraph>Concomitant Medications<sup>a</sup><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" colspan="5" styleCode="Rrule Botrule Toprule "><BR>                                    <paragraph>Dose of SELZENTRY Based on Renal Function</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td align="center" styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Normal</paragraph><BR>                                    <paragraph>(CrCl&gt;80 mL/min)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>Mild</paragraph><BR>                                    <paragraph>(CrCl &gt;50 and &#8804;80 mL/min)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>Moderate</paragraph><BR>                                    <paragraph>(CrCl &#8805;30 and &#8804;50 mL/min)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>Severe</paragraph><BR>                                    <paragraph>(CrCl &lt;30 mL/min)</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>End-Stage Renal Disease </paragraph><BR>                                    <paragraph>On Regular Hemodialysis</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Potent CYP3A inhibitors (with or without a CYP3A inducer)<sup>a</sup><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>150&#160;mg twice daily</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>150&#160;mg twice daily</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>150 mg twice daily</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>NR</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>NR</paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Lrule Botrule "><BR>                                    <paragraph>Other concomitant medications<sup>a</sup><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>300&#160;mg twice daily</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>300&#160;mg twice daily</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>300&#160;mg twice daily</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>300&#160;mg twice daily<sup>b</sup><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>300&#160;mg twice daily<sup>b</sup><BR>                                    </paragraph><BR>                                 </td><BR>                              </tr><BR>                              <tr><BR>                                 <td styleCode="Rrule Botrule Lrule "><BR>                                    <paragraph>Potent CYP3A Inducers (without a potent CYP3A inhibitor)<sup>a</sup><BR>                                    </paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>600&#160;mg twice daily</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>600&#160;mg twice daily</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>600&#160;mg twice daily</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>NR</paragraph><BR>                                 </td><BR>                                 <td align="center" styleCode="Rrule Botrule "><BR>                                    <paragraph>NR</paragraph><BR>                                 </td><BR>                              </tr><BR>                           </tbody><BR>                        </table><BR>                        <BR><BR><BR>NR = Not recommended.<BR>                        <BR>                           aSee Table 1 for the list of concomitant medications.<BR>                        <BR>                           bThe dose of SELZENTRY should be reduced to 150 mg twice daily if there are any symptoms of postural hypotension [see Warnings and Precautions (5.3)].<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>